

Filed on behalf of Patent Owner Genentech, Inc. by:

David L. Cavanaugh (Reg. No. 36,476)  
Owen K. Allen (Reg. No. 71,118)  
Robert J. Gunther, Jr. (*Pro Hac Vice to be filed*)  
Lisa J. Pirozzolo (*Pro Hac Vice to be filed*)  
Kevin S. Prussia (*Pro Hac Vice to be filed*)  
Andrew J. Danford (*Pro Hac Vice to be filed*)  
WILMER CUTLER PICKERING  
HALE AND DORR LLP  
1875 Pennsylvania Ave., NW  
Washington, DC 20006

Adam R. Brausa (Reg. No. 60,287)  
Daralyn J. Durie (*Pro Hac Vice to be filed*)  
DURIE TANGRI LLP  
217 Leidesdorff Street  
San Francisco, CA 94111

UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

CELLTRION, INC.,  
Petitioner,

v.

GENENTECH, INC.,  
Patent Owner.

---

Cases IPR2017-01374  
Patent 6,407,213

---

**PATENT OWNER'S MOTION TO SEAL**

**STATEMENT OF PRECISE RELIEF REQUESTED**

Pursuant to 37 C.F.R. §§ 42.14 and 42.54, Patent Owner Genentech, Inc. respectfully requests that the Board seal Exhibits 2001 (Laboratory Notebook 10098 (Leonard Presta)), 2002 (Laboratory Notebook 10823 (Leonard Presta)), 2003 (Laboratory Notebook 11268 (Paul Carter)), 2004 (Laboratory Notebook 11643 (Paul Carter)), 2005 (Laboratory Notebook 10840 (John Brady)), 2006 (Laboratory Notebook 11162 (John Brady)), 2007 (Excerpts from Laboratory Notebook 11008 (Ann Rowland)), 2008 (Excerpts from Laboratory Notebook 11297 (Tim Hotaling)), 2009 (Excerpts from Laboratory Notebook 11568 (Monique Carver)), 2010 (Interoffice Memorandum from Paul Carter to Leonard Presta and Dennis Henner), 2011 (Interoffice Memorandum from Paul Carter to Leonard Presta), 2012 (Synthetic DNA Requests), 2013 (Synthetic DNA Requests), 2014 (Protein Engineering of 4D5: Status Report), 2015 (Interoffice Memorandum re: RCC Meeting Minutes), 2016 (Declaration of Dr. Leonard G. Presta), 2017 (Declaration of Dr. Paul J. Carter), and 2018 (Declaration of John Ridgway Brady).

**REASONS FOR RELIEF REQUESTED**

Although “the default rule is that all papers filed in an *inter partes* review are open and available for access by the public,” a party may file a motion with the Board to seal confidential information that is protected from disclosure. *Garmin v.*

*Cuozzo*, IPR2012-00001, Paper No. 36. “The standard for granting a motion to seal is ‘for good cause.’” *Id.* (quoting 37 C.F.R § 42.54). The *Office Patent Trial Practice Guide*, 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012), states that the “rules identify confidential information in a manner consistent with Federal Rule of Civil Procedure (“FRCP”) 26(c)(1)(G), which provides for protective orders for trade secret or other confidential research, development, or commercial information.”

The parties have conferred and agreed to the provisions of the Modified Default Standing Protective Order set forth in Exhibit 2030, and have stipulated to be bound to the terms set forth therein. Exhibit 2031 shows the proposed modifications from the Default Standing Protective Order, to which the parties have stipulated, in redline.<sup>1</sup> The Modified Default Standing Protective Order provides:

Where confidentiality is alleged as to some but not all of the information submitted to the Board, the submitting party shall file confidential and non-confidential versions of its submission, together with a Motion to Seal the confidential version setting forth the reasons why the information redacted from the non-confidential version is

---

<sup>1</sup> The parties have stipulated to an identical modified default standing protective order in other proceedings. *See* IPR2017-01121, Paper 8, Ex. 2036; IPR2017-01122, Paper 8, Ex. 2036.

confidential and should not be made available to the public. The nonconfidential version of the submission shall clearly indicate the locations of information that has been redacted. The confidential version of the submission shall be filed under seal. The redacted information shall remain under seal unless, upon motion of a party and after a hearing on the issue, or *sua sponte*, the Board determines that some or all of the redacted information does not qualify for confidential treatment.

(Ex. 2030, Modified Default Standing Protective Order and Patent Owner's Certification of Agreement to Terms, at 3.)

Exhibits 2001-2009 are laboratory notebooks authored by several Genentech scientists. Exhibits 2001-2009 contain information pertaining to each scientist's work product during the course of his or her employment at Genentech, and are therefore "confidential research [and] development . . . information" pursuant to FRCP 26(c)(1)(G).

Exhibits 2010-2015 are internal communications within Genentech pertaining to confidential research and development activities being conducted by scientists at Genentech, and are therefore "confidential research [and] development . . . information" pursuant to FRCP 26(c)(1)(G). Furthermore, Exhibit 2015 was marked "CONFIDENTIAL" internally by Genentech.

Exhibits 2016-2018 are declarations by three Genentech scientists pertaining to confidential research and development activities related to the invention

described and claimed in U.S. Patent No. 6,407,213. The redacted portions of Exhibits 2016-2018 contain “confidential research [and] development . . . information” pursuant to FRCP 26(c)(1)(G).

Patent Owner therefore respectfully requests that the aforementioned materials remain under seal pursuant to the Proposed Modified Default Standing Protective Order.

Respectfully Submitted,

/David L. Cavanaugh/

David L. Cavanaugh  
Registration No. 36,476  
WILMER CUTLER PICKERING  
HALE AND DORR LLP  
1875 Pennsylvania Avenue, N.W.  
Washington, D.C. 20006  
david.cavanaugh@wilmerhale.com  
Tel.: 202-663-6000  
Fax: 202-663-6363

Dated: September 6, 2017